410例住院患者的利奈唑胺用药评估及影响因素分析  

Risk factors analysis and evaluation of linezolid used in 410 inpatients

作　　者：郭代红[1] 王丽[2] 陈超[1] 刘皈阳[1] 曹秀堂[3] 蔡芸[1] 王睿[1] 

机构地区：[1]解放军总医院药品保障中心,北京100853 [2]北京大学医学部药学院,北京100191 [3]解放军总医院医学统计室,北京100853

出　　处：《中国药物应用与监测》2011年第2期69-74,共6页Chinese Journal of Drug Application and Monitoring

基　　金：军队十一五科技攻关课题(08G139)

摘　　要：目的:了解并评价利奈唑胺的临床用药疗效及安全性,探究其引起血小板减少症可能的影响因素。方法:采用回顾性研究方法,收集我院2009年1月-2010年2月使用利奈唑胺的410例住院病人的用药资料,对其血小板计数相关的风险影响因素进行统计学回归分析。结果:410例使用利奈唑胺的患者有效率为84.63%,发生不良反应128例次,其中,血小板减少症78例(19.02%),高于国外报道(11%)。年龄>65岁、女性、治疗时间>28 d、基础血小板计数<200×109.L-1、联用3种以上抗生素等是引发血小板减少症的危险因素(P<0.05)。结论:利奈唑胺对革兰阳性球菌感染的临床疗效显著,其致血小板减少症发生率差异及相关影响因素应引起关注。Objective：The efficacy and safety of clinical therapy with linezolid were evaluated and the possible risk factors which may cause thrombocytopenia were analyzed.Methods：Data were collected from hospital information system among 410 patients who received linezolid between January 2009 and February 2010 on a daily basis.Risk factors associated with thrombocytopenia in patients who received linezolid were identified by logistic regression analysis.Results：Out of the 410 patients included in analysis,347 cases（84.63%） were effective.There were 128 adverse reactions,78 cases（19.02%） with thrombocytopenia,higher than that published overseas（11%）.Age above 65 years,female,treatment duration of more than 28 days,baseline platelet count of lower than 200×109.L-1 and combination with more than two antibiotics were the possible risk factors（P0.05）.Conclusion：Published data suggested that treatment with linezolid had significant effect on patients with infection of gram positive coccus.People should pay more attention to the differences about incidence rate of thrombocytopenia and relevant influencing factors.

关 键 词：利奈唑胺 临床疗效 血小板减少症 危险因素 

分 类 号：R978.1[医药卫生—药品] R969.4[医药卫生—药学]